Low serum levels of CCL2 are associated with worse prognosis in patients with Acute Coronary Syndrome: 2-year survival analysis

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author LEOCADIO, Paola Caroline Lacerda
MENTA, Penelope Lacrisio dos Reis
DIAS, Melissa Tainan Silva
FRAGA, Julia Rodrigues
GOULART, Alessandra Carvalho FMUSP-HC
SANTOS, Itamar Souza FMUSP-HC
LOTUFO, Paulo Andrade FMUSP-HC
BENSENOR, Isabela Martins FMUSP-HC
ALVAREZ-LEITE, Jacqueline Isaura
dc.date.issued 2019
dc.identifier.citation BIOMEDICINE & PHARMACOTHERAPY, v.109, p.1411-1416, 2019
dc.identifier.issn 0753-3322
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/29790
dc.description.abstract Inflammation is very important in Acute Coronary Syndrome (ACS) as well as in cardiac remodeling after an acute myocardial infarction (MI). Our study examined the prognostic value of Chemokine (C-C motif) ligand 2 (CCL2) in patients with ACS in the ERICO (Strategy of Registry of Acute Coronary Syndrome) study. We evaluated serum samples from 803 patients. The prognostic value of CCL2 was evaluated at the 2-year follow-up, according to cutoff points established by the median. Kaplan-Meier curves and Cox regression were used for analysis of all-cause mortality, cardiovascular mortality, and a combined outcome of fatal myocardial infarction or new non-fatal MI. There were 115 deaths from all causes, 78 deaths due to cardiovascular causes and 67 events in combined outcomes. CCL2 levels below the median (<= 100.9 pg/mL) were associated with increased risk of MI death or new non-fatal MI, even after model adjustment. Low serum levels of CCL2 shows a significant association with fatal or new non-fatal MI.
dc.description.sponsorship · Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [FAPESP 2012/14804-1]
· Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) [001]
dc.language.iso eng
dc.publisher ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
dc.relation.ispartof Biomedicine & Pharmacotherapy
dc.rights openAccess
dc.subject Acute Coronary Syndrome; CCL2; Coronary Artery Disease; Myocardial infarction; Prognosis
dc.subject.other monocyte chemoattractant protein-1; cardiovascular risk-factors; myocardial-infarction; mcp-1; inflammation; expression; biomarkers; mortality; registry; disease
dc.title Low serum levels of CCL2 are associated with worse prognosis in patients with Acute Coronary Syndrome: 2-year survival analysis
dc.type article
dc.rights.holder Copyright ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
dc.description.group LIM/20
dc.description.group LIM/51
dc.identifier.doi 10.1016/j.biopha.2018.10.087
dc.identifier.pmid 30551392
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author GOULART, Alessandra Carvalho:HU:SCPACEX-62
hcfmusp.author SANTOS, Itamar Souza:FM:MCM
hcfmusp.author LOTUFO, Paulo Andrade:FM:MCM
hcfmusp.author BENSENOR, Isabela Martins:FM:MCM
hcfmusp.author.external · LEOCADIO, Paola Caroline Lacerda:Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil
· MENTA, Penelope Lacrisio dos Reis:Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil
· DIAS, Melissa Tainan Silva:Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil
· FRAGA, Julia Rodrigues:Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil
· ALVAREZ-LEITE, Jacqueline Isaura:Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil
hcfmusp.origem.id WOS:000452539100154
hcfmusp.origem.id 2-s2.0-85056485256
hcfmusp.publisher.city ISSY-LES-MOULINEAUX
hcfmusp.publisher.country FRANCE
hcfmusp.relation.reference · Basra SS, 2016, HEART FAIL CLIN, V12, P31, DOI 10.1016/j.hfc.2015.08.004
· Beckowski M, 2018, INT J CARDIOL, V264, P165, DOI 10.1016/j.ijcard.2018.03.135
· Bentzon JF, 2014, CIRC RES, V114, P1852, DOI 10.1161/CIRCRESAHA.114.302721
· Buyukkaya E, 2013, AM J CARDIOL, V112, P187, DOI 10.1016/j.amjcard.2013.03.011
· Carulli MT, 2008, ANN RHEUM DIS, V67, P105, DOI 10.1136/ard.2006.067967
· Chinetti-Gbaguidi G, 2015, NAT REV CARDIOL, V12, P10, DOI 10.1038/nrcardio.2014.173
· Coll B, 2007, CLIN CHIM ACTA, V383, P21, DOI 10.1016/j.cca.2007.04.019
· Correia LCL, 2010, CLIN CHIM ACTA, V411, P540, DOI 10.1016/j.cca.2010.01.011
· de Winter CF, 2012, RES DEV DISABIL, V33, P1722, DOI 10.1016/j.ridd.2012.04.010
· Deo R, 2004, J AM COLL CARDIOL, V44, P1812, DOI 10.1016/j.jacc.2004.07.047
· Dewald O, 2004, AM J PATHOL, V164, P665, DOI 10.1016/S0002-9440(10)63154-9
· Dewald O, 2005, CIRC RES, V96, P881, DOI 10.1161/01.RES.0000163017.13772.3a
· Ding D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135713
· Frangogiannis NG, 2003, AM J PHYSIOL-HEART C, V285, pH483, DOI 10.1152/ajpheart.01016.2002
· Frangogiannis NG, 2008, PHARMACOL RES, V58, P88, DOI 10.1016/j.phrs.2008.06.007
· FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
· Gao W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023386
· Ghattas A, 2013, J AM COLL CARDIOL, V62, P1541, DOI 10.1016/j.jacc.2013.07.043
· Gonzalez-Quesada C, 2009, CURR ATHEROSCLER REP, V11, P131, DOI 10.1007/s11883-009-0021-y
· Goulart AC, 2013, CLINICS, V68, P431, DOI 10.6061/clinics/2013(03)RC02
· He G., 2011, ASS MCP 1 GENE 2518
· Kaikita K, 2004, AM J PATHOL, V165, P439, DOI 10.1016/S0002-9440(10)63309-3
· Libby P, 2014, CIRC RES, V114, P1867, DOI 10.1161/CIRCRESAHA.114.302699
· Makki N, 2015, J INTENSIVE CARE MED, V30, P186, DOI 10.1177/0885066613503294
· Melgarejo E, 2009, INT J BIOCHEM CELL B, V41, P998, DOI 10.1016/j.biocel.2008.07.018
· Morimoto H, 2006, CIRC RES, V99, P891, DOI 10.1161/01.RES.0000246113.82111.2d
· Nahrendorf M, 2010, CIRCULATION, V121, P2437, DOI 10.1161/CIRCULATIONAHA.109.916346
· Park HJ, 2008, INT J CARDIOL, V130, P409, DOI 10.1016/j.ijcard.2007.08.128
· Santos IS, 2015, ARQ BRAS CARDIOL, V105, P53, DOI 10.5935/abc.20150044
· Sun Y, 1996, CARDIOVASC RES, V31, P518
· Tarzami ST, 2002, J MOL CELL CARDIOL, V34, P209, DOI 10.1006/jmcc.2001.1503
· Vargas L., 2013, J HYPERTENS, V2, P1
· Ritter AMV, 2017, ARQ BRAS CARDIOL, V108, P331, DOI 10.5935/abc.20170033
· Wang JH, 2007, INT J CARDIOL, V115, P361, DOI 10.1016/j.ijcard.2006.03.019
· Weir RAP, 2010, CYTOKINE, V50, P158, DOI 10.1016/j.cyto.2010.02.020
· Widera C, 2013, CLIN CHEM, V59, P1497, DOI 10.1373/clinchem.2013.206185
· Yang F, 2002, EXP PHYSIOL, V87, P547, DOI 10.1113/eph8702385
dc.description.index MEDLINE
dc.identifier.eissn 1950-6007
hcfmusp.citation.scopus 0
hcfmusp.citation.wos 0
hcfmusp.affiliation.country Brasil


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics